Digital microfluidics comes of age: high-throughput screening to bedside diagnostic testing for genetic disorders in newborns.
Digital microfluidics comes of age: high-throughput screening to bedside diagnostic testing for genetic disorders in newborns.
复制标题
数字微流体会年龄：对新生儿遗传疾病的高通量筛查对床旁诊断测试。
DOI：
10.1080/14737159.2018.1495076
复制
发表时间：
2018-08
影响因子：
5.1
通讯作者：
Pamula V
中科院分区：
文献类型：
--
作者：
Millington D;Norton S;Singh R;Sista R;Srinivasan V;Pamula V
数字微流体（DMF）是一种新兴技术，具有适用于新生儿和高风险筛查遗传性代谢疾病和新生儿中存在的其他疾病的适当指标。本文回顾了过去十年来基于电润湿的DMF技术的发展，以实现其承诺，提供一个廉价的平台，在床边进行酶测定和靶向生物标志物测定。高通量DMF平台（称为SEEKER®）最近获得美国食品药品监督管理局（FDA）的授权，用于筛查新生儿的四种溶酶体贮积症（LSD），并部署在美国的新生儿筛查项目中。发展的试剂和方法来筛选LSDs和筛选中心的结果进行了审查。从一个更紧凑的DMF设备，执行适用于新生儿重症监护病房从小体积的血液疾病特异性测试面板的初步结果，也进行了审查。本综述的文献来源于PubMed中的主要作者和受试者检索。新生儿筛查是一项重要且非常成功的公共卫生计划。DMF技术为当前的检测平台增加了价值，这将有利于具有潜在遗传疾病的明显健康的新生儿和新生儿期出现症状的风险婴儿。
Digital microfluidics (DMF) is an emerging technology with the appropriate metrics for application to newborn and high-risk screening for inherited metabolic disease and other conditions that present in the newborn. This review traces the development of electrowetting-based DMF technology over the past ten years toward the fulfillment of its promise to provide an inexpensive platform to conduct enzymatic assays and targeted biomarker assays at the bedside. The high-throughput DMF platform, referred to as SEEKER®, was recently authorized by the United States Food and Drug Administration (FDA) to screen newborns for four lysosomal storage disorders (LSDs) and is deployed in newborn screening programs in the United States. The development of reagents and methods to screen for LSDs and results from screening centers are reviewed. Preliminary results from a more compact DMF device, to perform disease-specific test panels applicable in the neonatal intensive care unit from small volumes of blood, are also reviewed. Literature for this review was sourced using principal author and subject searches in PubMed. Newborn screening is a vital and highly successful public health program. DMF technology adds value to the current testing platforms that will benefit apparently healthy newborns with underlying genetic disorders and infants at-risk for conditions that present with symptoms in the newborn period.
登录
查看更多内容
影响因子：
1.3
作者：
Emani, Sirisha;Nelson, Lisa T.;Emani, Sitaram
通讯作者：
Emani, Sitaram
影响因子：
6.1
作者：
Fan, Shih-Kang;Yang, Hanping;Hsu, Wensyang
通讯作者：
Hsu, Wensyang
影响因子：
5.1
作者：
Hopkins, Patrick V.;Campbell, Carlene;Kiesling, Jami
通讯作者：
Kiesling, Jami
影响因子：
4.6
作者：
Hong J;Kim YK;Won DJ;Kim J;Lee SJ
通讯作者：
Lee SJ
DOI：
10.1146/annurev-anchem-062011-143028
发表时间：
2012-01-01
期刊：
ANNUAL REVIEW OF ANALYTICAL CHEMISTRY, VOL 5
影响因子：
--
作者：
Choi, Kihwan;Ng, Alphonsus H. C.;Wheeler, Aaron R.
通讯作者：
Wheeler, Aaron R.